# Elixir Medical: Transformation Unlocked > Elixir Medical is re\-imagining how radical medical technologies will breathe new life into vascular medicine\. Generated by Yoast SEO v28.2, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [OUS Sitemap](https://elixirmedical.com/ous/sitemap/) - [Careers](https://elixirmedical.com/us/careers/) - [Careers](https://elixirmedical.com/ous/careers/) - [LithiX HC\-IVL](https://elixirmedical.com/ous/lithix-hc-ivl/) - [Product Resources](https://elixirmedical.com/ous/product-resources/) ## Posts - [Production Supervisor](https://elixirmedical.com/production-supervisor/) - [BIOADAPTOR RCT](https://elixirmedical.com/bioadaptor-rct-4-year-results/): \

n=445\ An RCT evaluating the acute and long\-term safety and effectiveness of the DynamX Coronary Bioadaptor compared to contemporary drug\-eluting stents\. \ \The study showed:\ \ \1\.8% TLF at 12 months vs\. 2\.8% for DES\ \16% increase in blood flow\ \\-9% volume regression in lipid\-rich lesions vs\. \+10% for DES\ \66% reduction in TLF at 4 years vs\. DES\ \ - [DESyne BDS Plus RCT](https://elixirmedical.com/desyne-bds-plus-rct/): \

n=202\ A prospective, multicenter, single\-blind study evaluating the safety and efficacy of DESyne BDS Plus\. \ \Study results:\ \ \Achieved primary endpoint of TLF noninferiority\ \No stent thrombosis \(definite/probable\), CVD, or TV\-MI in the DESyne BDS Plus arm\ \Sustained low TLF \& TVF rates from 12 months to 24 months\ \ - [MY\-IVL](https://elixirmedical.com/my-ivl-intravascular-lithotripsy-in-complex-and-high-risk-pci-populations/): \(n=102, L=130\) \ A post\-market study to evaluate the safety and performance of LithiX™ HC\-IVL in a real\-world population with highly complex calcified lesions\. \ \The study showed:\ \ \96\.1% freedom from MACE \(30 days\)\ \96\.3% residual stenosis \<30% and without intra\-procedural MACE\ \113\.71% overall mean stent expansion\ \ - [PINNACLE I](https://elixirmedical.com/pinnacle-study-for-intravascular-hertz-contact-lithotripsy/): \(n=60, L=63\) \ LithiX™ HC\-IVL has been proven to successfully treat a wide range of lesion morphologies with 100% angiographic success, no device failure, and very little MACE\. \ \Results demonstrated:\ \ \98\.3% clinical success\†\\ \100% angiographic success\‡\\ \\>100% mean final stent expansion in OCT subset\§\\ \ \†Residual stenosis \<30% with no in\-hospital MACE through hospital discharge\ ‡ Stent delivery success, with residual stenosis \<50% and no serious angiographic complications\ § in eccentric and concentric calcific lesions and those with calcific nodules\\ ## ElementsKit items - [dynamic\-content\-megamenu\-menuitem16915](https://elixirmedical.com/elementskit-content/dynamic-content-megamenu-menuitem16915/) ## Leroux Portfolio - [People Power](https://elixirmedical.com/portfolio-item/people-power/) - [Compact Now](https://elixirmedical.com/portfolio-item/compact-now/) - [Design Projects](https://elixirmedical.com/portfolio-item/design-projects/) - [Logo Design](https://elixirmedical.com/portfolio-item/logo-design/) - [Product Design](https://elixirmedical.com/portfolio-item/product-design/) ## Popups - [Eligibility Quiz \- Arabic](https://elixirmedical.com/?post_type=popup&p=14263) - [Penafian Pasien](https://elixirmedical.com/?post_type=popup&p=12152) - [Example: Auto\-opening announcement popup](https://elixirmedical.com/?post_type=popup&p=12171) - [Eligibility Quiz](https://elixirmedical.com/?post_type=popup&p=12149) - [Patients Disclaimer](https://elixirmedical.com/?post_type=popup&p=12152) ## Popup Themes - [Default Theme](https://elixirmedical.com/?post_type=popup_theme&p=12067) - [Light Box](https://elixirmedical.com/?post_type=popup_theme&p=12068) - [Enterprise Blue](https://elixirmedical.com/?post_type=popup_theme&p=12069) - [Hello Box](https://elixirmedical.com/?post_type=popup_theme&p=12070) - [Cutting Edge](https://elixirmedical.com/?post_type=popup_theme&p=12071) ## Categories - [News](https://elixirmedical.com/category/news/) - [Careers](https://elixirmedical.com/category/careers/) - [OUS Site](https://elixirmedical.com/category/ous-site/) - [Clinical Evidence](https://elixirmedical.com/category/clinical-evidence/) - [Operations](https://elixirmedical.com/category/careers/operations/) ## Tags - [DynamX Coronary Bioadaptor System](https://elixirmedical.com/tag/dynamx-coronary-bioadaptor-system/) - [Clinical Trials](https://elixirmedical.com/tag/clinical-trials/) - [Careers](https://elixirmedical.com/tag/careers/) - [TCT Conference](https://elixirmedical.com/tag/tct-conference/) - [Clinical Data](https://elixirmedical.com/tag/clinical-data/) ## Categories - [Clients Page](https://elixirmedical.com/clients-category/clients-page/) - [Business Strategy](https://elixirmedical.com/clients-category/business-strategy/) - [Business Home](https://elixirmedical.com/clients-category/business-home/) - [Training Home](https://elixirmedical.com/clients-category/training-home/) ## Categories - [Business](https://elixirmedical.com/portfolio-category/business/) - [Innovation](https://elixirmedical.com/portfolio-category/innovation/) - [Success](https://elixirmedical.com/portfolio-category/success/) - [Branding](https://elixirmedical.com/portfolio-category/branding/) ## Tags - [Project](https://elixirmedical.com/portfolio-tag/project/) ## Categories - [Main Home](https://elixirmedical.com/team-category/main-home/) - [Business Strategy](https://elixirmedical.com/team-category/business-strategy/) ## Categories - [Business Strategy](https://elixirmedical.com/testimonials-category/business-strategy/) - [FS Home](https://elixirmedical.com/testimonials-category/fs-home/) - [Main Home](https://elixirmedical.com/testimonials-category/main-home/) - [Training Home](https://elixirmedical.com/testimonials-category/training-home/) ## Designations - [DynamX Hospitals](https://elixirmedical.com/?wpfm_designations=dynamx-hospitals) - [Bioadaptor Implanting Sites](https://elixirmedical.com/?wpfm_designations=bioadaptor-implanting-sites) ## Optional - [Sitemap index](https://elixirmedical.com/sitemap_index.xml)